Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs atezolizumab + bevacizumab in first-line PD-L1 high metastatic NSCLC
2018-003973-82Phase 2Active
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab monotherapy with Atezolizumab + bevacizumab (2 arms). Primary endpoint: Overall survival rate at 18 months. Started Jun 2021; status: active.
02
Drugs
atezolizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003973-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003973-82.